Table 3.
Subgroup analysis for study-related adverse events
| Constipation-predominant IBS (IBS-C) | Placebo, n (%) N = 40 | Elobixibat, n (%) | ||
|---|---|---|---|---|
| 5 mg N = 43 |
10 mg N = 39 |
15 mg N = 41 |
||
| Without IBS-C | ||||
| Number of patients | 28 | 26 | 29 | 30 |
| Number of patients with an adverse event | 2 | 9 | 9 | 7 |
| Proportion of patients (%) | 7.1 | 34.6 | 31.0 | 23.3 |
| 95% CI | 1.98–22.65 | 19.41–53.78 | 17.28–49.23 | 11.79–40.93 |
| With IBS-C | ||||
| Number of patients | 12 | 17 | 10 | 11 |
| Number of patients with an adverse event | 0 | 5 | 2 | 0 |
| Proportion of patients (%) | 0.0 | 29.4 | 20.0 | 0.0 |
| 95% CI | 0.00–24.25 | 13.28–53.13 | 5.67–50.98 | 0.00–25.88 |
CI confidence interval, IBS irritable bowel syndrome